Revolution Medicines, Inc.
C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors

Abstract:

The present disclosure relates to mTOR inhibitors. Specifically, the embodiments are directed to compounds and compositions inhibiting mTOR, methods of treating diseases mediated by mTOR, and methods of synthesizing these compounds.